賽昂生醫：革命性T細胞平台專利

At the heart of innovative vision lies our Armed-T™ Technology Platform, a pioneering approach to T-cell therapy that is both revolutionary with comprehensively robust patent portfolio.

The Armed-T™ Technology Platform

CytoArm is a pioneering biopharmaceutical company focused on developing the next generation of T-cell technology. Our innovative platform, Armed-T™ , is designed to create a diverse portfolio of T-cell products that target a wide range of cancers and autoimmune diseases through our unique bi-functional antibody (BsAb) technology.

Innovative Armed-T™ Manufacturing Technology

The Armed-T™ platform uses a unique Bi-functional Antibody (BsAb) approach, which allows simultaneous targeting of T cells and cancer cells, leading to highly specific and effective cancer treatment. Thus, the non-viral production process is not only faster, with manufacturing completed within 10 days, but also safer, reducing the risks associated with viral vectors and allowing for quicker deployment of therapies. The platform achieves over 90% purity in its T cell products, ensuring high safety and efficacy, which is a significant advantage over many traditional T cell therapies.

武裝型T細胞平台可開發多種疾病療法，滿足擴張中的市場需求

As global demand for innovative cancer treatments continues to grow, CytoArm’s Armed-T™ platform is uniquely positioned to seize significant market opportunities. Its adaptability enables the development of a diverse range of Armed-T™ products, collectively targeting over 50 different diseases. This versatility allows us to provide comprehensive solutions for various cancers and autoimmune conditions. Additionally, the broad applicability of our platform is safeguarded by our extensive patent protection, ensuring that CytoArm remains a leader in T-cell therapy innovation.

Armed-T™ Platform’s Comprehensive Patent fortress

CytoArm’s comprehensive patent portfolio for the Armed-T™ platform serves as a powerful “Right barrier”, effectively preventing other entities from replicating or commercializing similar T-cell therapies. By securing patents across multiple aspects of our Bi-functional Antibody (BsAb) technology and non-viral manufacturing process, we have established a strong intellectual property fortress. This not only safeguards our innovations but also ensures that CytoArm remains the exclusive provider of Armed-T™ therapies. Competitors are legally restricted from developing, producing, or marketing any technologies that infringe upon our patents, reinforcing our position as the sole leader in this revolutionary T-cell therapy approach.